Scarica l'app Stockscreener
2.43
2.80%
-0.07
Precedente Chiudi:
$2.50
Aprire:
$2.49
Volume 24 ore:
113.50K
Relative Volume:
0.06
Capitalizzazione di mercato:
$16.86M
Reddito:
-
Utile/perdita netta:
$-7.72M
Rapporto P/E:
-0.9207
EPS:
-2.6394
Flusso di cassa netto:
$-6.25M
1 W Prestazione:
-9.67%
1M Prestazione:
+37.69%
6M Prestazione:
-44.77%
1 anno Prestazione:
-52.91%
Intervallo 1D:
$2.40
$2.56
Intervallo di 1 settimana:
$2.30
$2.70
Portata 52W:
$1.55
$5.59
Edesa Biotech Inc Stock (EDSA) Company Profile
Nome
Edesa Biotech Inc
Settore
Industria
Telefono
(905) 475-1234
Indirizzo
100 SPY COURT, MARKHAM, ON
Confronta EDSA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
EDSA
Edesa Biotech Inc
|
2.43 | 16.86M | 0 | -7.72M | -6.25M | -2.6394 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Edesa Biotech Inc Borsa (EDSA) Ultime notizie
Biotech Stocks To Keep An Eye OnFebruary 13th - MarketBeat
Biotech Stocks To Keep An Eye On – February 13th - Defense World
Edesa Biotech Reports Fiscal 1st Quarter 2025 Results - GlobeNewswire
Edesa Biotech Advances Vitiligo Treatment Amidst Solid Financial Backing - TipRanks
Edesa Biotech Inc. (EDSA) reports earnings - Quartz
Edesa Biotech Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Edesa Biotech, Inc. SEC 10-Q Report - TradingView
Edesa's Q1 Report Reveals Major Vitiligo Drug Progress: $15M Cash Injection Fuels FDA Push - StockTitan
US Penny Stocks To Watch In February 2025 - Simply Wall St
Edesa Biotech secures $15 million for clinical program By Investing.com - Investing.com Nigeria
Novartis to acquire Anthos Therapeutics for up to $3.1 billion - MSN
Edesa Biotech, Inc. announced that it has received $14.999992 million in funding from Velan Capital Investment Management LP and another investor - Marketscreener.com
H: Riding the Market Waves of Growth and Decline in 2023 - The InvestChronicle
Edesa Biotech Inc (EDSA) Stock: A Comprehensive 52-Week Review - The InvestChronicle
Dow Jumps Over 100 Points; Deere Posts Upbeat Earnings - Benzinga
Stock market news: Moleculin Biotech +583.33%, Cloudastructure +105.68% among top gainers during midday trading - Business Upturn
Nasdaq Surges 150 Points; Cisco Earnings Top Views - Benzinga
Edesa Biotech shares jump on $15M private placement - MSN
Edesa Biotech (EDSA) Sees Sharp Stock Increase After Equity News - Stocks Telegraph
Stock market today: Moleculin Biotech +388.10%, Alpha Modus Holdings +156.52% among top gainers in early trading - Business Upturn
MAXONA Pharmaceuticals Completes Phase 1 Trials for Breakthrough Pain Therapy - MSN
US Stocks Edge Higher; Producer Prices Increase In January - Benzinga
Truist maintains Buy on Genmab stock, price target at $50 - MSN
Edesa Biotech announces $15 million private placement - MSN
Information Provided Pursuant to Early Warning Requirements with Respect to Par Nijhawan and Velan Capital - Financial Post
Edesa Biotech Announces $15.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules - Marketscreener.com
Edesa Biotech secures $15 million for clinical program - Investing.com India
Edesa Biotech Secures $15 Million in Private Placement to Advance Clinical Programs - TipRanks
Edesa Biotech announces $15M private placement priced at-the-market - TipRanks
Edesa Biotech Secures $15 Million for CXCL10 Antibody Program - TipRanks
Edesa Biotech Announces $15.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules - GlobeNewswire
Major Funding Alert: Edesa's $15M Deal Fuels Breakthrough Vitiligo Drug Development - StockTitan
Dallas City Council approves planning deal for 2026 World Cup - MSN
Mawson Finland announces private placement for up to C$5M - MSN
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)? - MSN
Jabil acquires CDMO Pii to support drug development customers - MSN
Obesity drug developer Aardvark files for IPO - MSN
EDSA: IND Expected in 2025 for EB06 for the Treatment of Vitiligo - Research Tree
EDSA: IND Expected in 2025 for EB06 for the Treatment of Vitiligo… - Yahoo Finance
Edesa Biotech Announces $4.36 million Registered Direct Offering - ACCESS Newswire
Is Raytheon the Best Defense and Aerospace Stock to Own in 2025? - The Globe and Mail
Edesa Biotech, Inc. (NASDAQ:EDSA) Short Interest Update - Defense World
EDSA Stock Touches 52-Week Low at $1.69 Amid Market Challenges - Investing.com
Edesa Biotech And 2 Other Promising US Penny Stocks For Your Radar - Simply Wall St
Edesa Biotech Reports Fiscal Year 2024 Results - The Manila Times
Edesa Biotech Slashes Operating Costs 20%, Secures Government Backing for ARDS Drug Development - StockTitan
Edesa Biotech stock hits 52-week low at $2.02 amid challenges - Investing.com Nigeria
Edesa Biotech Inc Azioni (EDSA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.27%
3.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):